Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Research output: Contribution to journalArticle

Author(s)

  • Matthew R. Sydes
  • Melissa R. Gannon
  • Mahesh K.B. Parmar
  • Mymoona Alzouebi
  • Gerhardt Attard
  • Alison J. Birtle
  • Susannah Brock
  • Richard Cathomas
  • Prabir R. Chakraborti
  • Audrey Cook
  • William R. Cross
  • David P. Dearnaley
  • Joanna Gale
  • Stephanie Gibbs
  • John D. Graham
  • Robert Hughes
  • Rob J. Jones
  • Robert Laing
  • Malcolm D. Mason
  • David Matheson
  • Duncan B. McLaren
  • Robin Millman
  • Joe M. O'Sullivan
  • Omi Parikh
  • Christopher C. Parker
  • Clive Peedell
  • Andrew Protheroe
  • Alastair W.S. Ritchie
  • Angus Robinson
  • J. Martin Russell
  • Matthew S. Simms
  • Narayanan N. Srihari
  • Rajaguru Srinivasan
  • John N. Staffurth
  • Santhanam Sundar
  • George N. Thalmann
  • Shaun Tolan
  • Anna T.H. Tran
  • David Tsang
  • John Wagstaff
  • Nicholas D. James

Department/unit(s)

Publication details

JournalEuropean Urology Oncology
DateAccepted/In press - 12 Jun 2018
DateE-pub ahead of print (current) - 14 Sep 2018
Number of pages10
Early online date14/09/18
Original languageEnglish

Bibliographical note

© 2018 The Authors

    Research areas

  • Cost-effectiveness analysis, Docetaxel, Prostate cancer

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations